Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.9 SEK 0.51%
Market Cap: 690.7m SEK

EV/EBIT
Enterprise Value to EBIT

-7.3
Current
-5.9
Median
16.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-7.3
=
Enterprise Value
1B SEK
/
EBIT
-140.8m SEK
Market Cap EV/EBIT
SE
Orexo AB
STO:ORX
686.7m SEK -7.3
US
Eli Lilly and Co
NYSE:LLY
749.3B USD 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
379.3B USD 16.7
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 15.1
CH
Roche Holding AG
SIX:ROG
206.4B CHF 11
CH
Novartis AG
SIX:NOVN
192.5B CHF 14.8
UK
AstraZeneca PLC
LSE:AZN
163.1B GBP 197.4
US
Merck & Co Inc
NYSE:MRK
211.4B USD 10.9
IE
Endo International PLC
LSE:0Y5F
184.8B USD 737.3
US
Pfizer Inc
NYSE:PFE
146.6B USD 11.1
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 1 875.6
Negative Multiple: -7.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.7
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.8
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.4
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.9
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.1
10%
1.1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-34.3
2-Years Forward
EV/EBIT
-27.1
3-Years Forward
EV/EBIT
-64.7